Clinical Study of Naoxintong Combined with Aspirin in the Treatment of Senile Ischemic Cerebrovascular Disease

In this study, 68 elderly patients with ischemic cerebrovascular disease (ICD) were randomly selected from June 2023 to June 2024, and were divided into group A (34 cases, conventional treatment + aspirin) and group B (34 cases, combined with Naoxintong on the basis of group A) by double-blind method, and the therapeutic effects of the two groups were compared. After treatment, the hemorheological indexes and NIHSS scores in group B were lower than those in group A (P < 0.05), the effective rate in group B was higher than that in group A (P < 0.05), and the incidence of adverse reactions in group B was higher than that in group A (P > 0.05). ICD patients treated with Naoxintong and aspirin can better improve hemorheology and neurological function, and the effect is significant and safe.